Stock 600211 TIBET RHODIOLA PHARMACEUTICAL HOLDING CO.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tibet Rhodiola Pharmaceutical Holding Co.

Equities

600211

CNE000000ZW7

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
36.6 CNY +0.49% Intraday chart for Tibet Rhodiola Pharmaceutical Holding Co. +2.81% -2.50%
Apr. 26 Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 26 Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2019 2022 2023 2024 2025 2026
Capitalization 1 5,665 8,906 12,099 11,797 - -
Enterprise Value (EV) 1 5,665 8,906 12,099 11,797 11,797 11,797
P/E ratio 14.1 x 18.5 x 11.6 x 8.86 x 7.39 x 6.1 x
Yield - - 1.96% - - -
Capitalization / Revenue 4.51 x - 3.86 x 3.43 x 2.9 x 2.44 x
EV / Revenue 4.51 x - 3.86 x 3.43 x 2.9 x 2.44 x
EV / EBITDA - - 12.5 x 9.4 x 8 x 6.7 x
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book 1.79 x - 2.78 x 2.07 x 1.62 x 1.28 x
Nbr of stocks (in thousands) 322,319 322,319 322,319 322,319 - -
Reference price 2 17.58 27.63 37.54 36.60 36.60 36.60
Announcement Date 3/12/20 3/10/23 3/26/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2022 2023 2024 2025 2026
Net sales 1 1,256 - 3,134 3,438 4,070 4,828
EBITDA 1 - - 968.2 1,255 1,475 1,762
EBIT 1 351.2 - 899.1 1,220 1,459 1,770
Operating Margin 27.96% - 28.69% 35.49% 35.85% 36.66%
Earnings before Tax (EBT) 1 352.7 - 898.2 1,220 1,459 1,770
Net income 1 312.3 369.8 800.9 1,025 1,226 1,487
Net margin 24.87% - 25.55% 29.81% 30.12% 30.8%
EPS 2 1.250 1.490 3.230 4.130 4.950 6.000
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 - - 0.7370 - - -
Announcement Date 3/12/20 3/10/23 3/26/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) 13.5% - 25% 23.4% 21.9% 21%
ROA (Net income/ Total Assets) - - - 19.6% 19.2% 18.7%
Assets 1 - - - 5,230 6,385 7,952
Book Value Per Share 2 9.830 - 13.50 17.70 22.60 28.60
Cash Flow per Share 2 1.970 - 4.290 3.740 4.830 5.630
Capex 1 - - - - - -
Capex / Sales - - - - - -
Announcement Date 3/12/20 3/10/23 3/26/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Tibet Rhodiola Pharmaceutical Holding Co.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
47.35
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
TIBET RHODIOLA PHARMACEUTICAL HOLDING CO. Stock Tibet Rhodiola Pharmaceutical Holding Co.
-2.50% 1.62B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.74% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.47% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.28% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
NOVARTIS AG Stock Novartis AG
+4.71% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
AMGEN INC. Stock Amgen Inc.
-4.23% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600211 Stock
  4. Financials Tibet Rhodiola Pharmaceutical Holding Co.